Drugs / Fosmidomycin
Fosmidomycin
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials | ||||||
| Phase 2 | NCT02198807 | Mar → Jul 2014 | Plasmodium falciparum malaria | Jomaa Pharma GmbH | Unknown | No outcome recorded |
| Phase 2 | NCT01361269 | Jun → Sep 2011 | malaria | Zentopharm GmbH | Unknown | No outcome recorded |
| Phase 2 | NCT01464138 | Sep 2010 → Sep 2011 | malaria | Jomaa Pharma GmbH | Completed | No outcome recorded |
| Phase 2 | NCT01464125 | Nov 2008 → Oct 2009 | malaria | Jomaa Pharma GmbH | Unknown | No outcome recorded |
| Phase 2 | NCT00217451 | Jun 2002 → Mar 2003 | malaria | Albert Schweitzer Hospital | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00214643 | Jun 2005 → Jul 2006 | malaria | Albert Schweitzer Hospital, Netherlands | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01002183 Comparator | — | Plasmodium falciparum malaria | Jomaa Pharma GmbH | Withdrawn | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fosmidomycin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01361269 ↗ |
| Known as | Fosmidomicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL203125 ↗ |
| Known as | FOSMIDOMYCIN SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL203125 ↗ |
| Known as | Fosmidomycine | ChEMBL registry synonym — accepted as the source's own label CHEMBL203125 ↗ |
| Action | Inhibit | “fosmidomycin as a potent inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase” NCT01002183 ↗ |
| Modality | Small molecule | — CHEMBL203125 ↗ |
| Route | Oral | “co-administered orally over three days” NCT01361269 ↗ |